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A B S T R A C T
Background: Platinum-based chemotherapy remains the standard of care for most lung cancer cases. However
chemoresistance is often developed during the treatment, limiting clinical utility of this drug. Recently, the
ability of tumor cells to adapt their metabolism has been associated to resistance to therapies. In this study, we
ﬁrst described the metabolic reprogramming of Non-Small Cell Lung Cancer (NSCLC) in response to cisplatin
treatment.
Methods: Cisplatin-resistant versions of the A549, H1299, and H460 cell lines were generated by continuous
drug exposure. The long-term metabolic changes, as well as, the early response to cisplatin treatment were
analyzed in both, parental and cisplatin-resistant cell lines. In addition, four Patient-derived xenograft models
treated with cisplatin along with paired pre- and post-treatment biopsies from patients were studied.
Furthermore, metabolic targeting of these changes in cell lines was performed downregulating PGC-1α ex-
pression through siRNA or using OXPHOS inhibitors (metformin and rotenone).
Results: Two out of three cisplatin-resistant cell lines showed a stable increase in mitochondrial function, PGC1-
α and mitochondrial mass with reduced glycolisis, that did not aﬀect the cell cycle. This phenomenon was
conﬁrmed in vivo. Post-treatment NSCLC tumors showed an increase in mitochondrial mass, PGC-1α, and a
decrease in the GAPDH/MT-CO1 ratio. In addition, we demonstrated how a ROS-mediated metabolism repro-
gramming, involving PGC-1α and increased mitochondrial mass, is induced during short-time cisplatin exposure.
Moreover, we tested how cells with increased PGC-1a induced by ZLN005 treatment, showed reduced cisplatin-
driven apoptosis. Remarkably, the long-term metabolic changes, as well as the metabolic reprogramming during
short-time cisplatin exposure can be exploited as an Achilles' heel of NSCLC cells, as demonstrated by the in-
creased sensitivity to PGC-1α interference or OXPHOS inhibition using metformin or rotenone.
Conclusion: These results describe a new cisplatin resistance mechanism in NSCLC based on a metabolic re-
programming that is therapeutically exploitable through PGC-1α downregulation or OXPHOS inhibitors.
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1. Background
Lung cancer is the most common cancer worldwide in terms of in-
cidence (1.2 million new cases per year, accounting for 16.7% of the
total cancer burden) and it is also the leading cause of cancer-related
death in the world (19.4% of the total). In addition to the human cost,
lung cancer has a high economic impact on both health services and
society as a whole [1,2].
About 85%–90% of lung cancers diagnosis are non-small cell lung
cancer (NSCLC). Present-day classiﬁcation of NSCLC takes into account
molecular alterations that may inﬂuence therapeutic decision.
However, at the moment we still do not have a drug-targetable driver
mutation identiﬁed for most NSCLC patients (near 85–90%) and thus,
platinum-based chemotherapy remains the standard of care. Moreover,
in that small percentage of patients with drug-targetable driver muta-
tions cisplatin-based therapy is also the principal approach following
targeted therapy [1,2].
On the other hand, although lung cancer treatments have pro-
gressed signiﬁcantly during the past years [3], and even more recently
with the appearance of immunotherapy, their cost-eﬀectiveness com-
pared with chemotherapy-based approaches will be an issue to address
[4]. Thus, cisplatin remains the main drug for treating NSCLC [5].
Sadly, during treatment, chemoresistance is often developed or it has to
be discontinued due to platinum toxicity limiting the clinical utility of
this drug. Therefore, a better understanding of cisplatin molecular
mechanisms of action and its resistance would greatly improve patients
outcome.
The mechanisms of cisplatin resistance are complex, involving di-
verse strategies and pathways [5]. Although altered energetic meta-
bolism is one of the cancer hallmarks [6], little has been shown in its
role in chemoresistance [7].
Mitochondria are organelles known to be the powerhouse of the
cell, responsible for the oxidative phosphorylation (OXPHOS). In this
process the acetyl CoA from glycolisis or fatty-acid oxidation powers
the tricarboxylic acid cycle (TCA) that generates reduced cofactors.
These cofactors are able to transfer electrons to the OXPHOS system
which, through a chain of redox reactions, ﬁnally reduce oxygen to
water. Some of these reactions produce ROS as a byproduct [8]. Si-
multaneously, during this process, protons are pumped into the inter-
membrane space generating what is known as Mitochondrial Inner
Membrane Potential (MIMP) that is ﬁnally dissipated through Complex
V generating ATP.
The classic view of tumor’s metabolism is the well-known Warburg
eﬀect. According to this theory, the tumor cells increase their aerobic
glycolysis reducing the OXPHOS function in order to boost the supply of
metabolic intermediates used in anabolic processes [9–11].
However, under some circumstances, tumor cells have the ability to
adapt their metabolism to diﬀerent environments and treatments, in-
creasing adaptability and tumor resistance to therapies [7,8]. In this
sense, an increase of the OXPHOS function has been described for some
tumors, although there is no data for NSCLC and cisplatin. These
adaptation processes may be performed by controlling the mitochon-
drial biogenesis, which is largely controlled by the transcriptional
coactivator peroxisome proliferator-activated receptor gamma coacti-
vator-1 alpha (PGC-1α). Theoretically, these metabolic changes open a
therapeutic opportunity to target resistances by using metabolic in-
hibitors [12,13].
Metformin has aroused great interest over the last years due to its
association with lower cancer incidence in type two diabetic patients
and better overall survival in cancer patients [14]. Metformin is also an
inhibitor of the complex I of the OXPHOS system. However, its role in
OXPHOS modulation in relation with cisplatin has not been studied in
NSCLC. Furthermore, metformin is a drug widely used for its anti-
diabetic properties, and has been in use for more than ﬁfty years
without any important interactions with most cancer treatments. These
characteristics make metformin really interesting for cancer therapy
due to its possible application, which would be much more direct
avoiding most of the limiting steps in drug-development [15].
In this study we generated cis-diamminedichloroplatinum(II)
(CDDP)-resistant versions of 3 diﬀerent NSCLC cell lines (A549, H1299
and H460) to characterize the stable metabolic changes associated with
increased CDDP resistance and also to evaluate the early changes in
response to CDDP treatment. Patient Derived Xenografts (PDX) models
treated with CDDP and paired pre- and post-treatment tumor biopsies
of NSCLC patients were also studied. Finally, we used these changes as a
therapeutic target of CDDP-resistant cells. This work provides a new
insight into cisplatin resistance mechanism in NSCLC cells that may
lead to the design of novel therapeutic approaches.
2. Methods
2.1. Patients, cell lines and reagents
Stage III NSCLC patients who had pre- and post-treatment paired
samples were retrospectively selected. A549, H1299, and H460 were
obtained from the ATCC. All cells were cultured routinely in DMEM,
with 10% Fetal Bovine Serum (FBS) and Penicillin Streptomycin
(Gibco). Cisplatin (Accord, 1mg/mL) was obtained from the Oncology
Service of the Hospital Puerta de Hierro Majadahonda. ZLN005,
Rotenone, CCCP, and NAC were purchased from Sigma.
2.2. Cell viability assays
Cells were set up at 3× 103 cells per well of a 96-well plate and
were cultured in DMEM overnight. The next morning the medium was
refreshed with DMEM containing the diﬀerent treatments according to
ﬁgure legends. Cell viability was assayed by Cell Counting Kit-8 (CCK-
8) (Dojindo EU GmbH, Munich, Germany) according to the manu-
facturer’s protocol.
2.3. Glucose and galactose growth curves
Cell growth was evaluated after seeding 6 well plates at a density of
25,000 cells/well and growing the cells for 4 days in DMEM containing
either 4.5 g/L glucose or 0.9 g/L galactose. The cells were harvested and
counted every 24 h. Population doubling times were calculated using
Doubling Time Software v1.0.10 (http://www.doubling-time.com).
Assays were performed by duplicate in at least 3 independent experi-
ments.
2.4. Cell cycle, MIMP, mitochondrial mass and ROS using ﬂuorescent
molecular probes
Cell cycle was determined using Vybrant™ DyeCycle™ Violet Stain.
Cytoplasmic ROS were assessed using 2’,7’-dichlorodihydroﬂuorescein
diacetate (H2DCFDA). 1 h of serum starvation was used as positive
control for ROS measurements. The mitochondrial inner membrane
potential (MIMP) was evaluated using tetramethyl rhodamine ester
(TMRE). CCCP was used as a negative control for MIMP assesment. The
mitochondrial mass was evaluated using Mitotracker Green FM (MTG).
All the ﬂuorescent probes were purchased from Molecular Probes®.
After addition of the ﬂuorophores (5 μM Vybrant, 30 μM DCFHDA,
100 nM TMRE, 100 nM MTG) and incubation at 37 °C for 30min in the
dark, the cells were collected in DMEM and analyzed immediately with
a Cytomic FC500 MPL ﬂow cytometer (Beckman Coulter). Forward and
side scatter were used to gate the viable population of cells, and the
mean ﬂuorescence intensity was determined with MXP software
(Beckman Coulter). Experiments were performed in duplicate on at
least three independent passages.
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2.5. Glucose consumption
The glucose consumption was determined through the measurement
of the concentration present in the cell medium over time. To do this,
3× 105 cells were seeded in a 6-well plate. The next day, the medium
was removed and 500 μL of fresh DMEM was added. After 6 h of in-
cubation the concentration present in the medium was determined. To
measure the concentration of glucose in the medium, an Accu-Check
Performa glucometer (Roche) was calibrated and used. Both the sam-
ples and the standard curve (500-0.15 g/L) were diluted ½ with dis-
tilled water before the measurement. The results are shown as mg of
glucose consumed at 6 h. At least three independent measurements
were obtained to generate the mean.
2.6. Oxygen consumption
The oxygen consumption of intact cells was measured in DMEM at
37 °C using a Clark-type oxygen electrode (Hansatech Instruments).
Basal respiration was calculated as the oxygen consumption rate minus
the non-mitochondrial respiration after KCN 1mM addition. At least
three independent measurements were obtained to generate the mean.
2.7. OXPHOS blue native PAGE
Mitochondria were puriﬁed from cell cultures as described [16].
Protein concentrations were determined using the microBCA protein kit
(Thermo Scientiﬁc). To obtain native mitochondrial proteins, pellets
were solubilized with 4 g digitonin (Sigma) per gram of protein in 1.5 M
aminocaproic acid, 50mM Bis-Tris, pH 7.0. Blue native electrophoresis
was performed as described [17]. NDUFA9 (Abcam, ab14713) was used
for the immunodetection of OXPHOS supercomplexes I + III2+IV.
SDHA (Abcam, ab14715) was used for normalization. Quantiﬁcation of
4 diﬀerent blots from 2 diﬀerent extracts was done using ImageJ.
2.8. Immunoﬂuorescence
Cells were ﬁxed with paraformaldehyde 4%, incubated overnight
with TOM20 antibody (Santa Cruz Biotechnology, sc-17764, 1/50).
Alexa Fluor 488 anti-mouse (Invitrogen Life Technologies, 1/500) was
used as secondary antibody. Nuclei were stained with Topro-3
(Invitrogen Life Technologies, 1/1000). Five images of each sample
were collected with a TCS SP5 confocal microscope (Leica
Microsystems) equipped with 20×HCX PL APO (0.7 numerical aper-
ture). Two channels were acquired sequentially with the following ex-
citation and emission parameters: (488 nm, 500–540 nm) for TOM20
signal, and (633 nm, 645–750 nm) for Topro-3. Data processing and
quantiﬁcation of ﬂuorescence signal were performed with LASF SOF-
TWARE VERSION 2.6.07266.
2.9. mRNA expression analysis
The RNA from cells was extracted using the “RNeasy mini Kit with
DNAse” (Qiagen). The RNA from FFPE tumors was extracted using the
High Pure FFPET RNA isolation kit (Roche). The cDNA was synthetized
using the “NZY First-Strand cDNA Synthesis Kit” (NZYtech). PGC-1α
(Hs01016719_m1) LDHA (Hs01378790_g1), MCT4 (Hs00358829_m1),
GAPDH (Hs02758991_g1), MT-CO1 (Hs02596864_g1) mRNA levels
were measured by qRT-PCR using Taqman® gene expression assays. TBP
(Hs00427621_m1) was used as endogenous control [18].
2.10. Western blotting
Catalase, MnSOD, AIF and BcL2 expression was analyzed on cell
extracts using speciﬁc antibodies from Sigma (C0979), Millipore
(06–984) Abcam (ab32516) and SantaCruz (sc-7382), respectively.
Immunodetection of γ-Tubulin (Sigma, T6557) was used as protein
loading control. Appropriate horseradish peroxidase coupled secondary
antibodies were used and peroxidase activity was assessed by enhanced
chemoluminescence (Amersham).
2.11. Patient derived xenograft models
Four diﬀerent PDX models from four NSCLC patients were gener-
ated as described previously [19]. All the treatments were carried out in
mice from passage two with bilateral palpable tumors. At least two
mice per group were intraperitoneal injected with 2,5 mg/kg CDDP or
vehicle two times per week in non-consecutive days. After the treat-
ments the animals were euthanized and the tumors were collected.
2.12. siRNA transfection
Cells were transfected 24 h prior to experiments with Silencer™
Select siRNA targeted to PGC-1α (s21394, sequence 5’- > 3’: CCUGU
UUGAUGACAGCGAAtt) and nontargeting control (Silencer™ Select
Negative Control No. 1) using Lipofectamine RNAiMAX according to
the manufacturer’s instructions (Thermo Scientiﬁc).
2.13. Apoptosis measurement
Cells were seeded in a 24-well plate in DMEM. The next day, the
medium was changed to DMEM or DMEM containing diﬀerent treat-
ments (5 μM CDDP and/or 20 μM ZLN005). After 48 h of treatments,
apoptosis was evaluated by ﬂow cytometry using the Annexin V, FITC
Apoptosis Detection Kit (Dojindo) and by confocal microscopy using the
DeadEnd™ Fluorometric TUNEL system (Promega).
For ﬂow cytometry studies, the cells were harvested, washed twice
in PBS and resuspended in 50 μL of 10-fold diluted Annexin V binding
solution. 1 μL of Annexin V-FITC conjugated and Propidium Iodide
were added to the cells and incubated for 15min at room temperature.
Finally, the cells were additionally diluted with 150 μL of 10-fold di-
luted Annexin V binding solution and immediately analized by ﬂow
cytometry. Forward and side scatter were used to gate the population of
cells. The graph bars represent the mean percentage of Annexin positive
cells from 4 measurements.
For confocal microscopy studies, the cells were ﬁrst washed twice in
PBS, ﬁxed 20min at 4 °C in paraformaldehyde 4% and labeled ac-
cording to manufacturer’s instructions. TO-PRO-3 was used as coun-
terstain to visualize all nuclei.
2.14. Statistics
The results were presented as the mean ± SD (Standard deviation).
Unpaired two-tailed Student’s t-test was used for statistical analysis
among groups. For multiple comparisons in Fig. 5 (Supplementary
Table 1) ANOVA with Tukey’s post-hoc test was carried out. Diﬀerences
were considered to be statistically signiﬁcant when the p-value was<
0.05 (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001).
3. Results
3.1. Generation of cisplatin resistant cell lines
As a ﬁrst step in the study of metabolic changes associated with
cisplatin resistance in NSCLC, our goal was to obtain CDDP-resistant
cell lines.
Thus, starting from three of the most common NSCLC cell lines from
diﬀerent origins (A549 primary tumor, H1299 lymph node and H460
pleural eﬀusion), resistant versions were obtained after three months of
treatment with 5 μM CDDP. After this selection process, cells were
evaluated for their vulnerability to CDDP treatment (Fig. 1A–C) and
their IC50 were calculated. As might be expected, the results showed
that the continuous CDDP treatment led to the development of an
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increased resistance in the three cell lines, similarly to what happens in
patients. Signiﬁcant diﬀerences were seen in all the 3 cell lines from
3 μM to 12 μM cisplatin dose. Following experiments were done with
5 μM of cisplatin dose.
Since CDDP aﬀects the DNA replication process, in order to exclude
that the continous CDDP treatment would had selected for cells with a
more quiescent phenotype and metabolism, we studied the cell cycle of
parental and CDDP-resistant cells. The results showed no diﬀerences in
any of the cell cycle phases (G1, S, G2) between parental and CDDP-
resistant cell lines (Fig. 1D–F). There were also no diﬀerences in the rate
of proliferation during their handling in cell culture (data not shown).
3.2. Cisplatin resistant cell lines show an increased oxidative metabolism
and mitochondrial biogenesis
Once we had three diverse NSCLC cellular models for resistance to
CDDP treatment, we proceed to characterize the metabolic changes
associated to this stable increase in CDDP resistance (Fig. 2).
The vast majority of tumor cells show an altered balance between
glycolytic and mitochondrial function. To analyze the glycolytic capa-
city of the cells, the glucose consumption from the cell media was
measured. A decrease in glucose consumption was observed for the cell
lines H1299 and H460 CDDP-resistant compared to their parental
versions, but no diﬀerences were detected between parental and CDDP-
resistant A549 cells (Fig. 2A). In a similar way, this reduction in glucose
consumption was accompanied by a downregulation of LDHA, MTC4
and GAPDH mRNA levels, reinforcing the idea of a reduced glycolysis in
H1299 and H460 CDDP-resistant cell lines (Supplementary Figure 1).
On the other hand, we measured the mitochondrial inner membrane
potential (MIMP) since it is a good subrogate of the mitochondrial
function. The results showed a signiﬁcant increase in the MIMP com-
pared to the parental cell lines for the H1299 and H460 CDDP-resistant
Fig. 1. Generation of CDDP-resistant cell lines. After continuous treatment of the cell lines (A) A549, (B) H1299, and (C) H460 with 5 μM CDDP, resistant versions
of the cell lines were obtained. The graphs represent the percentage of viable cells (Y-axis) after 48 h of diﬀerent CDDP treatments (X-axis) relative to untreated cells.
Cell cycle analysis for parental and CDDP-resistant cell lines (D–F). Data are means from at least three diﬀerent experiments. Error bars indicate standard deviation.
Student’s t-test p-value was considered to be statistically signiﬁcant when was< 0.05 (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001).
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cell lines, but not for the A549 CDDP-resistant cell line (Fig. 2B).
To conﬁrm that there was a change in the oxidative metabolism and
not only in the MIMP that could be produced by other mechanisms, we
decided to measure the galactose to glucose (Gal/Glu) growth ratio,
indicative of the OXPHOS capacity of the cells (Fig. 2C), and the oxygen
consumption of these cells using a Clark-type oxygen electrode
(Fig. 2D). Similarly to MIMP, the results showed an increase of the Gal/
Glu growth ratio oxygen consumption for the H1299 and the H460
CDDP-resistant cell lines, although no diﬀerences were seen for the
A549 cells.
Fig. 2. Metabolic reprograming in
CDDP resistant cell lines. (A) Glucose
consumption of cell lines. (B)
Mitochondrial inner membrane poten-
tial was measured by ﬂow cytometry
with the ﬂuorescent probe TMRE. (C)
Relationship between the growth rate
in galactose and glucose of the parental
cell lines and resistant to CDDP, an in-
crease in this ratio is indicative of an
increase in OXPHOS function. (D)
Oxygen consumption of intact cells was
measured using a Clark-type electrode.
(E) BN-PAGE of OXPHOS super-
complexes in H1299 and H460 cells.
(F–G) Mitochondrial Mass measured by
Mitotracker Green and TOM20
Immunoﬂuorescence. (H) Relative
PGC1α mRNA levels for CDDP-resistant
compared to parental cell lines. (I)
Upper panel, Catalase and MnSOD le-
vels measured by Western blot. “P” and
“R” letters indicate Parental and
Resistant cell lines. Lower panel, re-
lative ROS levels measured using the
ﬂuorescent probe DCFHDA. Data are
means from at least three diﬀerent ex-
periments and are represented as per-
centage of their respective parental cell
line. Student’s t-test p-value was con-
sidered to be statistically signiﬁcant
when was< 0.05 (* = P ≤ 0.05,
** = P ≤ 0.01, *** = P ≤ 0.001).
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Fig. 3. Metabolic changes associated to Cisplatin treatment in PDX models and Patients biopsies. PGC-1αmRNA, TOM20 and GAPDH/MT-CO1 levels relative
to untreated controls for tumors obtained from PDX2 and PDX3 models (A). Analysis of NSCLC pre- and post-treatment tumor biopsies analysing TOM20, SUVmax
and GAPDH/MT-CO1 ratio levels (B). Error bars indicate standard deviation. Student’s t-test p-value was considered to be statistically signiﬁcant when was<0.05
(* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001).
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To explain the mechanism behind the increase in MIMP and oxygen
consumption, we studied the levels of OXPHOS complexes by BN-PAGE
in H1299 and H460 cell lines in which there was a net increase in
OXPHOS function (Fig. 2E). Strikingly, the results showed no signiﬁcant
diﬀerences in the amount of mitochondrial supercomplexes
I + III2+IV. An explanation for this contradiction (increased oxygen
consumption and MIMP but no changes in the amount of complexes)
could be an increase of mitochondrial biogenesis. In this way, the mi-
tochondrial network would harbor the same density of OXPHOS com-
plexes but having more mitochondrial mass, the total amount of OX-
PHOS complexes per cell would be higher.
To test this hypothesis, we measured the levels of mitochondrial
mass using the molecular probe Mitotracker Green (MTG) (Fig. 2F), as
well as through immunoﬂuorescence using TOM20 antibody (Fig. 2G).
The results showed an increase of the mitochondrial mass for the CDDP-
resistant H1299 and H460 cell lines. On the contrary, no changes were
observed for the CDDP-resistant A549 cell line. Interestingly, this cell
line also did not show an increase in the OXPHOS function.
These results were completed with a gene expression analysis for
PGC-1α, an oxidative stress inducible regulator of mitochondrial bio-
genesis (Fig. 2H). The expression levels for PGC-1α were signiﬁcantly
increased in the H1299 and H460 CDDP-resistant cell lines compared to
their parental cells. However, no changes were observed for the A549
CDDP-resistant cell line, similarly to that observed for mitochondrial
mass, MIMP and oxygen consumption.
To check if the increase of PGC-1α could lead to a reduction in the
oxidative stress and therefore participate as resistance mechanism, we
evaluated the levels of antioxidant proteins and also the steady state
ROS levels (Fig. 2I). The immunoblot showed an increased mitochon-
drial superoxide dismutase (MnSOD), but reduced catalase levels, in
H1299 and H460 CDDP-resistant cells fully consistent with the ob-
served increase in the steady state levels of ROS, mainly H202, mea-
sured with DCFHDA. However, the results showed an increase in ROS
levels for the all the CDDP-resistant cell lines, regardless of their PGC-
1α levels or the change in OXPHOS metabolism. These results would
suggest that the antioxidant capacity of this cells do not participate in
the increased CDDP-resistance. If this were the case, it would be more
logical to observe lower levels of ROS in the CDDP-resistant cell lines.
3.3. Cisplatin treatment induces an increase in mitochondrial mass in PDX
models and patients tumors
To conﬁrm the results in cell lines, we decided to analyze whether
this metabolism change occurred in a similar way in patient derived
xenograft (PDX) models. Four PDX models from four NSCLC patients
were generated.
Mice were randomly distributed in two groups, controls and CDDP-
treated and PGC-1α levels were evaluated (Fig. 3A). Tumors from two
out of four PDX showed an increase in PGC-1α levels (PDX2 and PDX3)
after CDDP treatment. No diﬀerences were seen for PDX4 and PDX1
(Supplementary Figure 2). Additionally, for PDX2 and PDX3, mi-
tochondrial mass was evaluated by Immunoﬂuorescence of TOM20 and
the ratio of GAPDH/MT-CO1 mRNA was calculated. In concordance
with their increased PGC-1α levels, there was a signiﬁcant increase in
mitochondrial mass as well as a reduction in the GAPDH/MT-CO1 ratio
after CDDP treatment.
In addition, we decided to analyze whether this change could also
be observed in pre- and post-treatment tumor biopsies of NSCLC
patients. Due to the diﬃculty of obtaining this type of paired pre- and
post-treatment samples, stage III NSCLC patients were selected since
their treatment is based in platinum doublet and their clinical routine
includes a pre-treatment diagnostic biopsy and a post-treatment sur-
gical biopsy. However, from ten patients only three samples were re-
trieved with enough material for the analysis. From all patients that
were tested, an increase in the levels of mitochondrial mass was ob-
served after CDDP treatment in the tumor cells, although this increase
only was statistically signiﬁcant in two of them (Fig. 3B). Anyhow,
when the data from the three patients are combined, signiﬁcative dif-
ferences are observed.
Furthermore, FDG-PET images of these patients were available for
pre- and post-treatment phases. From these images the SUVmax was
calculated in both timepoints, showing a decrease of this parameter
after treatment. Moreover, when possible due to biopsies size, RNA was
extracted and the GAPDH/MT-CO1 mRNA ratio was calculated. The
results from Patient 1 and Patient 2 show a decrease in GAPDH with
and increase in MT-CO1 mRNA levels, which leads to a signiﬁcant
decrease in the GAPDH/MT-CO1 mRNA ratio.
3.4. Metabolic targeting of parental and CDDP-resistant NSCLC cells using
PGC-1α siRNA or OXPHOS inhibitors
The OXPHOS function characterization would indicate that the in-
crease of mitochondrial biogenesis and OXPHOS function is a common
phenomenon in cell lines, PDX and patients treated with CDDP.
Following this hypothesis, we investigated if this group of CDDP-re-
sistant cells with enhanced OXPHOS function could be targeted with
the siRNA downregulation of PGC-1α as well as using drugs that acts
inhibiting the mitochondrial function.
For these studies we worked with the cell line H1299 since its
CDDP-resistant version is the one that showed a greater increase of the
MIMP. We used the cell line A549 as a negative control for which this
phenomenon was not found.
First all of, we tested if the downregulation of PGC-1α was able to
reduce the mitochondrial mass. Using especiﬁc siRNA against PGC-1α,
we reached approximately a 70–80% reduction of PGC-1α expression
compared to control siRNA (Fig. 4A). In these conditions, the PGC-1α
interference reduced the mitochondrial mass measured with MTG in all
the cell lines. Interestingly, the reduction for the parental H1299 line
was not statistically signiﬁcant, thus decreasing the diﬀerences in mi-
tochondrial mass levels between parental and resistant when PGC was
silenced (Fig. 4B).
Afterward, we measured the cell’s sensitivity to PGC-1α down-
regulation (Fig. 4C). The interference of PGC-1α decreases the cell
viability in all the cases, however this eﬀect was signiﬁcantly higher for
the H1229 CDDP resistant cell line compared to its parental version. On
the other hand, no diﬀerences in PGC-1α interference sensitivity were
found between parental and CDDP resistant A549 cell lines.
Secondly, we tested if the antidiabetic drug, metformin, was capable
of reducing the MIMP of the cell lines. The addition of metformin to the
A549 and H1299 cell lines decreased their MIMP regardless of their
CDDP resistance (Fig. 4D).
After that, we evaluated the eﬀect of diﬀerent metformin con-
centrations on the viability of the parental and CDDP resistant cells
(Fig. 4E). The results show a decrease in cell viability with increasing
metformin concentrations. Remarkably, this eﬀect is much greater in
the case of the H1299 CDDP resistant cell line compared to its parent
Fig. 4. Cisplatin resistance increase Metformin, Rotenone and PGC-1α siRNA sensitivity. (A) PGC-1α mRNA interference levels (B) PGC1a siRNA interference
decreases the Mitochondrial mass measured with MTG. (C) PGC-1α siRNA sensitivity in parental and CDDP resistant cells (D)Metformin treatment reduces the MIMP
in both A549 and H1299 cell lines, regardless of their CDDP resistance. (E and F)Metformin and rotenone sensitivity was evaluated for the A549 and H1299 parental
cell lines and for their respective CDDP resistant versions. The graphs represent the percentage of viable cells (Y-axis) after 48 h of diﬀerent metformin treatments (X-
axis). Data are means from at least three diﬀerent experiments and are represented as percentage of untreated cells. Error bars indicate standard deviation. Student’s
t-test p-value was considered to be statistically signiﬁcant when was<0.05 (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001).
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Fig. 5. Changes in MIMP and ROS in early response to CDDP treatment. Parental and CDDP resistant cell lines were treated with 5 μM CDDP. Changes in ROS
(A), PGC1-alpha levels (B), Mitochondrial Mass (C) and MIMP (D) were evaluated. Eﬀect of concomitant 10mM NAC in ROS and MIMP changes induced by CDDP
treatment at 24 h (E). Cell cycle analysis and MIMP during CDDP treatment (F). Bars are means from at least three diﬀerent experiments and are represented as
percentage of untreated parental cells. Error bars indicate standard deviation. Student’s t-test p-value was considered to be statistically signiﬁcant when was<0.05
(* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001).
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line; on the other side, no diﬀerences were seen for the line A549 CDDP
resistant compared to its parental cell line.
In addition, we assessed the sensitivity of cell lines to rotenone, a
speciﬁc inhibitor of mitochondrial Complex I and therefore of the
OXPHOS function (Fig. 4F and Supplementary Figure 3). Similar to
metformin, there are no signiﬁcant diﬀerences in rotenone sensitivity
between parental and CDDP-resistant A549 cells. However, the H1299
CDDP-resistant cells are signiﬁcantly more sensitive to rotenone than
their parental version.
3.5. Cisplatin treatment induces a cycle-independent, ROS-mediated,
metabolic reprograming
The results obtained with the resistant cell lines led us to wonder if
these stable metabolic changes observed could be consequence of a
selection process that happens during short time exposure to CDDP. In
order to do so, we studied the early response to the drug. To simplify
the interpretation of the results, only the statistical analysis between the
basal condition and after treatment is shown (Fig. 5). The remaining
comparisons are shown in Supplementary Table 1.
Since PGC-1α is induced by ROS, we studied whether cisplatin was
able to increase cellular ROS levels. For this purpose, we analyzed the
ROS levels 16 h after CDDP treatment in the diﬀerent cell lines
(Fig. 5A). The results showed an increase in ROS when the parental
cells are treated with 5 μM CDDP for 16 h. Similarly, this early change
of ROS in response to treatment also occurs in resistant lines, which
further augment their increased parameters. Therefore, this phenom-
enon seems to be common to parental and resistant cell lines. In ad-
dition, this conﬁrms that the CDDP-resistant cell lines do not exhibit a
more eﬀective antioxidant response to CDDP treatment, which dis-
misses the possibility that their resistance is mediated by a reduction in
oxidative damage.
Then we checked whether there was a process of metabolic repro-
gramming induced by short time CDDP treatment. We evaluated the
levels of PGC1 alpha (Fig. 5B), mitochondrial mass (Fig. 5C) and MIMP
(Fig. 5D) after 24 h of 5 μM CDDP exposure. The results showed an
Fig. 6. ZLN005 treatment induces an increase in mi-
tochondrial mass and reduces CDDP-sensitivity in cell
lines. (A) ZLN005 treatment induces PGC-1α mRNA le-
vels (B) Mitochondrial mass measured by MTG and
TOM20 IHC in ZLN005 treated cells for 48 h. Bars are
means from at least three diﬀerent experiments and are
represented as percentage of untreated parental cells.
ZLN005 reduces sensitivity to CDDP decreasing apoptosis.
(C) Percentage of viable cells after 48 h of treatments. (D)
Graph bars represent the mean percentage of Annexin
positive cells from 4 measurements. Error bars indicate
standard deviation. Student’s t-test p-value was con-
sidered to be statistically signiﬁcant when was<0.05
(* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001).
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increase in all the parameters. Interestingly, this increase occurs in the
three cell lines, although the CDDP-resistant line A549 does not have a
stable increase in any of them.
In addition, this metabolic reprograming induced by CDDP was
avoided by antioxidant treatment. The simultaneous treatment with
10mM N-Acetyl Cysteine (NAC) reduced the ROS levels in CDDP
treated cells below controls. Curiously, in this situation the NAC
treatment avoided the MIMP increase, indicating that this process is
mediated by ROS (Fig. 5E).
On the other hand, since it is described that CDDP is an intercalating
agent that hinders S phase, we tested if this MIMP increase at short
times, could be the consequence of alterations in the cell cycle (Fig. 5F).
Measuring the cell cycle we observed that, certainly, treatment with
CDDP hold back cells in S-G2 phase, decreasing the proportion of cells
in G1. However, this eﬀect is lower in the resistant lines. Regarding the
mitochondrial function, cells in S-G2 phase showed more MIMP,
therefore part of the increase we saw is because the cells are detained in
this phase. In any case, if we compare the cells within the same cell
cycle phase, there is a cell-independent increase of MIMP during CDDP
treatment.
3.6. Induction of PGC-1α and mitochondrial mass by ZLN005 treatment
reduces CDDP associated apoptosis
To isolate the eﬀect of PGC-1α increase from the rest of changes
accumulated in the CDDP-resistant cells, we decided to treat the par-
ental cells with the compound ZLN005 (a PGC-1α transcriptional acti-
vator) to check if we could reproduce the CDDP resistant phenotype.
This compound is described to increase PGC-1α levels in muscle,
however, no data exist for cancer cells [20].
Parental cell lines treated with ZLN005 increases their PGC-1α
mRNA levels in a dose-dependent manner at 48 h (Fig. 6A). Similarly,
the ZLN005 treatment induces a rise in the levels of mitochondrial mass
for the parental cell lines (Fig. 6B).
Next, we checked whether there was a reduction in the CDDP sen-
sitivity associated to the induction of PGC-1α and mitochondrial mass.
The results show how ZLN005 treatment reduces CDDP sensitivity in a
dose-dependent manner (Fig. 6C). Moreover, we analyzed the me-
chanism behind this reduction in CDDP sensitivity and we veriﬁed that
apoptosis induced by CDDP was reduced by ZLN005 treatment (Fig. 6D
and Supplementary Figure 4). Therefore, there is an association be-
tween the expression of PGC-1α, the mitochondrial mass and the CDDP
induced apoptosis.
3.7. Metabolic targeting with PGC-1α siRNA or OXPHOS inhibitors in
concomitance with CDDP in parental and CDDP resistant NSCLC cells
Since we saw an increase of OXPHOS function, also as an early re-
sponse to CDDP treatment, and this metabolic reprograming seems to
be key for CDDP induced apoptosis, we tested if concomitant metabolic
targeting of OXPHOS function through PGC-1α siRNA, metformin or
rotenone treatment might enhance the eﬀect of cisplatin.
We proceeded in a similar manner, ﬁrst we analyzed whether siRNA
was able to reduce the early rise in MIMP induced by CDDP (Fig. 7A).
The results show that PGC-1α siRNA is able to control the increase of
mitochondrial mass induced by cisplatin in the two lines A549 and
H1299, for both parental and CDDP-resistant versions. Subsequently,
we measured the cell viability using PGC-1α siRNA in the presence of
concomitant 5 μM CDDP (Fig. 7B). Downregulation of PGC-1α increases
the eﬀect of CDDP in all the cases. However, the diﬀerences in CDDP
sensitivity between A549 parental and its CDDP-resistant version are
maintained. On the other hand, due to an increased sensitivity to PGC-
1α downregulation in H1299 CDDP-resistant cells, the diﬀerences be-
tween parental and CDDP resistant H1299 cells are lost.
Secondly, we tested if metformin treatment was able to avoid the
increase of MIMP produced by short time exposure to CDDP (Fig. 7C).
The metformin treatment restraint the MIMP rise induced by CDDP for
all the cases. Furthermore, the treatment with metformin or rotenone
eliminates the diﬀerences between parental and resistant cell lines to
cisplatin treatment for both cell lines (Fig. 7D and E). The diﬀerences
between parental and resistant cells are no longer signiﬁcant from a
concentration of 1mM metformin or 1 nM rotenone for both A549 and
H1299 cell lines.
4. Discussion
Cisplatin remains a cornerstone for treating NSCLC, however little is
known about the mechanisms of resistance associated with changes in
cell’s metabolism. In this work, using cell models, PDX models and
biopsies of patients with NSCLC, we have analyzed the metabolic
changes produced by cisplatin treatment. In addition, taking advantage
of these changes we have identiﬁed an increased sensitivity to OXPHOS
inhibition or PGC-1α interference in CDDP-resistant cell lines.
In our study, we generated resistant versions from three diﬀerent
cell lines after continued treatment with cisplatin for three months. Two
out of three cell lines showed stable changes towards an increased
OXPHOS function and reduced glycolisis (increased MIMP, galactose to
glucose growth ratio, mitochondrial mass and oxygen consumption but
reduced glucose consumption). However, the three of them responded
in a similar way increasing ROS, MIMP and mitochondrial mass as an
early response to CDDP treatment.
Interestingly, in our case, the metabolic changes were not associated
with a more quiescent phenotype [21], since no stable changes were
observed in the cell cycle phases. This opens up the possibility of
changes in metabolism after chemotherapy, regardless of the increase
in quiescent phenotype, as it has been described so far [12]. In order to
check whether the mechanism of metabolism modiﬁcation that we
describe can be parallel to the typical alterations of proteins related to
apoptosis, we have analyzed the levels of BCL2 and AIF (Supplementary
Figure 5). As previously described, we saw a decrease in AIF (pro-
apoptosis) and an increase in BCL2 (anti-apoptosis), which would in-
dicate that our mechanism does not replace other classical mechanisms
already described of cisplatin resistance [22].
PGC-1α is the master regulator of mitochondrial biogenesis and
metabolic energy metabolism. In our case we saw a stable increase of
this transcriptional activator, precisely, in the two cell lines (H1299 and
H460) that showed an increased OXPHOS function. In the same way,
the CDDP-resistant A549 cell line, without changes observed in the
OXPHOS function, did not show an increase in PGC-1α expression.
Perhaps due to the diﬃculty of obtaining post-treatment re-biopsies
in NSCLC, there is no literature that study this metabolism repro-
gramming after treatment in NSCLC biopsies. To solve this problem and
conﬁrm our results beyond the cell lines, we ﬁrst decided to retro-
spectively analyze CDDP treated PDX models available in the labora-
tory. Similar to the results obtained in cell lines, the results in PDX
models show an increase in PGC-1α and mitochondrial mass, as well as
a reduction of the GAPDH/MT-CO1 ratio mRNA levels, for two out of
four PDX models.
Despite the diﬃculty of obtaining paired samples, we obtained en-
ough biopsy material for the analysis in 3 patients. In all cases, we saw
an increase in mitochondrial mass levels and a decrease in the GAPDH/
MT-CO1 ratio, strongly suggesting a metabolic reprograming towards a
more oxidative metabolism [23]. Similar results have been observed in
post-treatment tumor biopsies from colon cancer patients [24].
This metabolic change associated with the treatment could also
have an implication in glucose uptake and therefore in PET imaging
when evaluating the treatment response or the disease extent.
In our experience the resistant CDDP lines are less glycolytic, si-
milarly in patients the post-neoadjuvant SUVmax is also lower. In ad-
dition, the post-treatment samples in both, the PDX and the patients,
showed a decrease in the GAPDH/MT-CO1 ratio that has already been
correlated with the levels of SUVmax in NSCLC [23]. Perhaps due to
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this process of metabolism reprogramming in post-treatment cells (with
an increase in mitochondrial function and a decrease in glucose con-
sumption), the SUVmax post-treatment drop is not a prognostic factor,
as it would not be a good indicator of the pathological response [25].
All these results in diﬀerent models and tumor biopsies indicate a
process of metabolic reprogramming towards a greater OXPHOS
Fig. 7. Metabolic targeting in concomitance with CDDP in parental and CDDP resistant NSCLC cells. PGC-1α siRNA reduces the MTG increase produced by
CDDP (A). Eﬀect of concomitant PGC-1α siRNA interference on cell viability (B). Metformin treatment reduces the MIMP increase produced by CDDP treatment in
both A549 and H1299 cell lines (C). Metformin and Rotenone eliminates the diﬀerences between parental and resistant cell lines to cisplatin treatment for both A549
and H1299 cells (D and E). The graphs represent the percentage of viable cells (Y-axis) after 48 h of diﬀerent metformin or rotenone treatments (X-axis). Data are
means from at least three diﬀerent experiments and are represented as percentage of untreated cells. Error bars indicate standard deviation. Student’s t-test p-value
was considered to be statistically signiﬁcant when was< 0.05 (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001).
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function against the Warburg Eﬀect. Most tumor cells prefer using
aerobic glycolysis despite the lower energy yield thereof (in comparison
to the use of the more eﬃcient OXPHOS system), since this “Warburg
metabolism” is adapted to sustain exponential growth [11,26]. How-
ever, as our results indicate, there is an increase in OXPHOS function
associated to CDDP treatment. A series of recent reports with similar
results for other tumors strongly support our observations [24,27–33].
Similar to our results in NSCLC, it has been recently described how
diﬀerent cisplatin-resistant lung cancer cell lines showed a decreased
glucose consumption with an increased OXPHOS function [34]. How-
ever, the authors describe an increase in glutamine dependence that we
do not ﬁnd in our CDDP-resistant cell lines (data not shown). Thus, to
our knowledge, despite the importance of platinum treatments in
NSCLC, this mechanism of metabolic reprograming associated with
CDDP resistance has not been demonstrated in this type of tumors until
this study.
Regarding the mechanism, PGC-1α can be triggered by oxidative
damage and chemotherapy in cancer cells [35]. Supporting these re-
sults, we saw an increase in ROS and PGC-1α shortly after treatment.
Furthermore, treatment with the antioxidant NAC prevents the increase
of ROS and the increase of mitochondrial function induced by CDDP,
which would support that this metabolism reprogramming is induced
by ROS.
In fact, treatment of parental cells with the PGC-1α inducer ZLN005,
reduces sensitivity to CDDP by increasing resistance to apoptosis. The
increase of mitochondrial mass and OXPHOS performance has been
associated with a reduction in treatment-induced apoptosis [28,36].
Since a loss of MIMP is key for apoptosis triggering, a strong possibility
would be that the higher MIMP would withstand better possible ﬂuc-
tuations in this parameter and then hamper the apoptosis triggering.
Besides that, cisplatin binds with greater aﬃnity to mtDNA compared
to nuclear DNA. Thus, having higher levels of mitochondrial mass
would reduce the CDDP toxic eﬀect on the cell [37].
Our hypothesis is that these mechanisms, as well as others yet to be
fully explored, would produce under short-term treatment an ad-
vantage for cells with an increased OXPHOS phenotype, which in the
long-term treatment scenario would lead to cells with a stable increased
OXPHOS function (Fig. 8).
On the other hand, PGC-1α is also involved in the antioxidant re-
sponse, controlling the expression of detoxifying enzymes [38]. In-
creased antioxidant response mediated by PGC-1α has been described
as a mechanism of treatment resistance in melanoma and ovarian
cancer [24,39–41] However, in our case, the ROS levels measured with
DCFHDA were signiﬁcantly increased in all the CDDP-resistant cell
lines. Remarkably, the ROS increase occurs both, as a stable modiﬁca-
tion in CDDP-resistant cell lines and also as an early response to short
cisplatin exposure in all of the cell lines studied. Thus, in our experi-
ence, it appears that PGC-1α levels do not have suﬃcient inﬂuence on
ROS detoxiﬁcation during CDDP treatments, making it diﬃcult to hy-
pothesize a greater tolerance to CDDP-induced oxidative stress in re-
sistant lines as the main mechanism of CDDP resistance. As a matter of
fact, the increase of ROS correlates with the reduction of apoptosis in
diﬀerents scenarios [8,42,43].
In addition, we investigated if this group of resistant cells with en-
hanced OXPHOS could be targeted inhibiting the mitochondrial func-
tion by means of diﬀerent treatments (Metformin, Rotenone and PGC-
1α siRNA) and under diﬀerent approaches (alone or in concomitance
with CDDP).
We demonstrated that both, the silencing of PGC-1α and the treat-
ment with the mitochondrial inhibitors metformin or rotenone reduced
the viability of the cell lines proportionally to their OXPHOS require-
ments. Thereby, the reduction was greater in the H1299 CDDP-resistant
cell line, in which an increase of the OXPHOS function, compared to the
parental version, was observed. However, the A549 CDDP-resistant
line, for which no increase in any OXPHOS parameter was observed,
maintained the same proﬁle of sensitivity to the diﬀerent treatments.
On the other hand, the concomitant treatment of CDDP with met-
formin, rotenone or the silencing of PGC-1α increases the eﬀect of
CDDP in all cases. In fact, the combined therapy of metformin or ro-
tenone with CDDP eliminates the diﬀerences of sensitivity between
parental and resistant lines for both A549 and H1299 cell lines.
Likewise, the combined therapy of PGC-1α siRNA and CDDP eliminates
the diﬀerences of sensitivity between parental and resistant lines for the
H1299 line but not for the A549 line.
Metformin is a drug commonly used for its antidiabetic properties,
although in the last years it has aroused an interest for its antitumor
role [44]. Regarding to bioenergetics, it has recently been described
that metformin inhibits the Complex I of the mitochondrial electron
transport chain [45] and reduces the ﬂow of glucose- and glutamine-
derived metabolic intermediates into the tricarboxylic acid cycle [46].
Compatible with this, our study showed that the addition of metformin
decreases the MIMP, thus explaining the diﬀerential sensitivity between
the cell lines. The similar results between the eﬀect of rotenone and
metformin reinforce the CI inhibition mechanism of metformin over
other non-OXPHOS eﬀects. There are numerous retrospective studies in
diﬀerent tumor types including NSCLC, which support the antitumor
role of metformin and its relationship with chemoradiotherapy treat-
ments [47,48]. A possible explanation for the best prognosis of cancer
patients taking metformin, could be due to its role as OXPHOS inhibitor
wich is key, as our ﬁndings indicate, for the chemotherapy resistance
phenotype.
5. Conclusion
In summary, an increase in the mitochondrial mass, and therefore
OXPHOS function, is a recurrent mechanism of resistance to cisplatin
treatment in NSCLC. Importantly, this characteristic of cisplatin-re-
sistant cells can be therapeutically used through the inhibition of PGC-
1α or the use of mitochondrial inhibitors. In any case, this metabolic
reprogramming does not occur in all the cases analyzed, being neces-
sary the validation of predictive markers of this resistance process. This
would be key for the success of future clinical trials since would allow
the identiﬁcation of patients who would beneﬁt from metabolism tar-
geted treatments.
Fig. 8. Proposed metabolic reprogramming
model associated to CDDP treatment in
NSCLC. Short-term changes (Left side) and
Long-term changes (Right side) are shown. Cells
with increased mitochondrial Mass and OXPHOS
function are selected during short exposure to
CDDP leading to stable OXPHOS changes during
long term treatment. The ellipses show the
pharmacological or genomic approaches used in
this study that block (in red) or increase (in
green) this mechanism. NAC: N-Acetyl Cysteine,
Metf: Metformin, Rot: Rotenone, siRNA: PGC-1α
siRNA.
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